93960-20-4 Usage
Uses
Used in Pharmaceutical Research and Development:
L-3-Pyridylalanine hydrochloride is utilized as a key intermediate in the synthesis of peptides and proteins for research purposes. Its unique structure allows for the exploration of novel drug candidates that can target specific biological pathways, potentially leading to the development of new therapeutic agents.
Used in Neuroscience and Neuropharmacology:
In the field of neuroscience, L-3-Pyridylalanine hydrochloride is studied for its potential to influence neurotransmission and receptor activity in the brain. Its interaction with neural systems could offer insights into the mechanisms of various neurological disorders and contribute to the advancement of neuropharmacological treatments.
Used in Chemical Synthesis:
L-3-Pyridylalanine hydrochloride serves as a versatile building block in organic synthesis, particularly for the creation of complex organic molecules with potential applications in medicine, agrochemicals, and other industries. Its reactivity and structural features make it a valuable component in the design and synthesis of new compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 93960-20-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,3,9,6 and 0 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 93960-20:
(7*9)+(6*3)+(5*9)+(4*6)+(3*0)+(2*2)+(1*0)=154
154 % 10 = 4
So 93960-20-4 is a valid CAS Registry Number.
InChI:InChI=1/C8H10N2O2.ClH/c1-6(8(11)12)10-7-3-2-4-9-5-7;/h2-6,10H,1H3,(H,11,12);1H/t6-;/m0./s1
93960-20-4Relevant academic research and scientific papers
Anthranilic acid based CCK1 receptor antagonists: Preliminary investigation on their second "touch point"
Varnavas, Antonio,Lassiani, Lucia,Valenta, Valentina,Mennuni, Laura,Makovec, Francesco,Hadjipavlou-Litina, Dimitra
, p. 563 - 581 (2007/10/03)
In this phase of structure-affinity relationship study of VL-0395, a new anthranilic acid based CCK1 selective antagonist, we propose a series of unnatural aminoacidic derivatives. The result of this work is the identification of a new CCK ligand, which possesses an affinity (IC50 = 35 nm) one order of magnitude greater than the lead and, as a general rule, it points out how the hypothesized receptorial pocket which accommodates the Phe residue allows much more structural modification than that interacting with the N-terminal group. Hence, the modification of the C-terminal pharmacophoric group of our lead VL-0395 can not only enhance the affinity of anthranilic acid derivatives but can modulate the selectivity for one CCK receptor subtype or afford mixed antagonists.
